Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy XTL Biopharmaceuticals stock

Own XTL Biopharmaceuticals stock in just a few minutes.

XTL Biopharmaceuticals Ltd is a biotechnology business based in the US. XTL Biopharmaceuticals shares (XTLB) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in XTL Biopharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – XTLB – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

XTL Biopharmaceuticals share price

Use our graph to track the performance of XTLB stocks over time.

XTL Biopharmaceuticals shares at a glance

Information last updated 2021-03-10.
52-week range$0.63 - $4.17
50-day moving average $3.41
200-day moving average $2.64
Wall St. target price$30.00
PE ratio 9.5835
Dividend yield N/A (0%)
Earnings per share (TTM) $0.20

Buy XTL Biopharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy XTL Biopharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is XTL Biopharmaceuticals under- or over-valued?

Valuing XTL Biopharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of XTL Biopharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

XTL Biopharmaceuticals's P/E ratio

XTL Biopharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 10x. In other words, XTL Biopharmaceuticals shares trade at around 10x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

XTL Biopharmaceuticals financials

Gross profit TTM $0
Return on assets TTM -8.06%
Return on equity TTM -29.71%
Profit margin 0%
Book value $1.20
Market capitalisation $18.7 million

TTM: trailing 12 months

Shorting XTL Biopharmaceuticals shares

There are currently 28,167 XTL Biopharmaceuticals shares held short by investors – that's known as XTL Biopharmaceuticals's "short interest". This figure is 460.1% up from 5,029 last month.

There are a few different ways that this level of interest in shorting XTL Biopharmaceuticals shares can be evaluated.

XTL Biopharmaceuticals's "short interest ratio" (SIR)

XTL Biopharmaceuticals's "short interest ratio" (SIR) is the quantity of XTL Biopharmaceuticals shares currently shorted divided by the average quantity of XTL Biopharmaceuticals shares traded daily (recently around 31296.666666667). XTL Biopharmaceuticals's SIR currently stands at 0.9. In other words for every 100,000 XTL Biopharmaceuticals shares traded daily on the market, roughly 900 shares are currently held short.

However XTL Biopharmaceuticals's short interest can also be evaluated against the total number of XTL Biopharmaceuticals shares, or, against the total number of tradable XTL Biopharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case XTL Biopharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 XTL Biopharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable XTL Biopharmaceuticals shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against XTL Biopharmaceuticals.

Find out more about how you can short XTL Biopharmaceuticals stock.

XTL Biopharmaceuticals share dividends

We're not expecting XTL Biopharmaceuticals to pay a dividend over the next 12 months.

Have XTL Biopharmaceuticals's shares ever split?

XTL Biopharmaceuticals's shares were split on a 1:5 basis on 9 February 2017. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your XTL Biopharmaceuticals shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for XTL Biopharmaceuticals shares which in turn could have impacted XTL Biopharmaceuticals's share price.

XTL Biopharmaceuticals share price volatility

Over the last 12 months, XTL Biopharmaceuticals's shares have ranged in value from as little as $0.625 up to $4.17. A popular way to gauge a stock's volatility is its "beta".

XTLB.US volatility(beta: 0.76)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while XTL Biopharmaceuticals's is 0.7603. This would suggest that XTL Biopharmaceuticals's shares are less volatile than average (for this exchange).

XTL Biopharmaceuticals overview

XTL Biopharmaceuticals Ltd. , a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd.

Frequently asked questions

What percentage of XTL Biopharmaceuticals is owned by insiders or institutions?
Currently 19.947% of XTL Biopharmaceuticals shares are held by insiders and 8.678% by institutions.
When does the fiscal year end for XTL Biopharmaceuticals?
XTL Biopharmaceuticals's fiscal year ends in December.
Where is XTL Biopharmaceuticals based?
XTL Biopharmaceuticals's address is: 5 Badner Street, Ramat Gan, Israel, 5218102
What is XTL Biopharmaceuticals's ISIN number?
XTL Biopharmaceuticals's international securities identification number is: US98386D3070
What is XTL Biopharmaceuticals's CUSIP number?
XTL Biopharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 98386D109

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site